These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30880808)

  • 1. 340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.
    Fauer A; Friese CR
    Clin J Oncol Nurs; 2019 Apr; 23(2):217-219. PubMed ID: 30880808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
    Faraj KS; Caram MEV; Shahinian VB; Hollenbeck BK
    Cancer; 2024 Sep; 130(18):3077-3081. PubMed ID: 38804732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
    Liu ITT; Wang J; Sarpatwari A; Kesselheim AS; Feldman WB
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31158. PubMed ID: 38970222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
    Kantarjian HM; Chapman R
    J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program.
    Owsley KM; Bradley CJ
    Health Aff (Millwood); 2023 Jun; 42(6):785-794. PubMed ID: 37276477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US Hospital Service Availability and New 340B Program Participation.
    Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
    JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
    Levengood TW; Conti RM; Cahill S; Cole MB
    Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
    Jung J; Xu WY; Kalidindi Y
    Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
    Conti RM; Bach PB
    Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
    Ruley M; Belcher M; Sayre H; Coustasse A
    Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 340B Drug Pricing Program and hospital provision of uncompensated care.
    Desai SM; McWilliams JM
    Am J Manag Care; 2021 Oct; 27(10):432-437. PubMed ID: 34668672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.